Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Dr Alkassis on Cathepsin Protease Expression and Its OS Association With T-DXd in Metastatic Breast Cancer

December 11th 2025

Samer Alkassis, MD, PhD, discusses how cathepsin protease expression may correlate with survival outcomes to trastuzumab deruxtecan in metastatic breast cancer.

Dr Hamilton on First-Line Tucatinib-Based Maintenance in HER2+ Metastatic Breast Cancer

December 10th 2025

Erika P. Hamilton, MD, discusses data from HER2CLIMB-05 evaluating tucatinib plus trastuzumab/pertuzumab first-line maintenance in HER2-positive breast cancer.

Sacituzumab Govitecan Maintains QOL Benefit Over Chemotherapy in Previously Untreated TNBC

December 10th 2025

PRO data from ASCENT-03 showed that the mean change in physical functioning from baseline to week 25 favored sacituzumab govitecan over chemotherapy.

Sacituzumab Govitecan Fails to Meet Primary PFS End Point in First-Line HR+/HER2– mBC

December 10th 2025

Sacituzumab govitecan did not improve PFS per BICR vs chemotherapy after endocrine therapy in hormone-receptor–positive/HER2-negative breast cancer.

Abemaciclib Monotherapy Shows Efficacy After CDK4/6 Inhibition in HR+/HER2– Breast Cancer

December 10th 2025

Abemaciclib monotherapy displayed a clinical benefit in some patients with HR+/HER2– breast cancer after CDK4/6 inhibitor therapy.

Multimodal AI Model Prognostic for Long-Term Recurrence Following Treatment for Early Breast Cancer

December 10th 2025

The multimodal ICM+ model was prognostic for long-term recurrence following treatment in early breast cancer.

Giredestrant Improves iDFS Compared With Endocrine Therapy in ER+, HER2– Breast Cancer

December 10th 2025

Giredestrant improved invasive disease-free survival vs endocrine therapy in ER-positive, HER2-negative, medium- and high-risk early breast cancer.

Adjuvant Aromatase Inhibition Is Associated With Improved DFS, TTDR in HR+/HER2+ Breast Cancer

December 10th 2025

Adjuvant AI therapy improved DFS and TTDR vs a SERM in patients with hormone receptor–positive, HER2-positive early breast cancer.

Dr Rimm on Conceptual Considerations Surrounding ADC Mechanisms in Breast Cancer

December 10th 2025

David Rimm, MD, PhD, discusses key conceptual considerations and discrepancies regarding the mechanisms of action of ADCs in breast cancer treatment.

Dr Vincent-Salomon on Persisting Gaps in Clinical Interpretation of Invasive Lobular Carcinoma

December 9th 2025

Anne Vincent-Salomon, PR, MD, PhD, HDR, highlights persistent gaps that continue to challenge reproducibility and clinical interpretation in the diagnostic classification of invasive lobular carcinoma.

Experts Highlight HR+ and TNBC Trials to Watch Ahead of SABCS 2025

December 8th 2025

Leading clinicians preview anticipated HR+ and TNBC studies at SABCS 2025.

Dr Jhaveri on the FDA Approval of Imlunestrant for ESR1+ Breast Cancer

December 5th 2025

Komal Jhaveri, MD, FACP, discusses the clinical implications of the FDA approval of imlunestrant for pretreated, ESR1-mutated advanced breast cancer.

Dr Quiroga Shares Breast Cancer Insights

December 3rd 2025

Dionisia Quiroga, DO, PhD, discusses breast cancer insights.

Revisit Every OncLive On Air Episode From November 2025

December 2nd 2025

In case you missed any, read a recap of every episode of OncLive On Air that aired in November 2025.

Experts Unpack the Most Notable NCCN Guideline Changes Heading Into 2026

December 1st 2025

Read the most notable updates to the latest versions of the NCCN Clinical Practice Guidelines in Oncology across tumor types ahead of 2026.

FDA Approves Osvyrti and Jubereq in High Fracture Risk Populations, Including in Breast and Prostate Cancer

November 20th 2025

Denosumab-desu (Osvyrti and Jubereq) received FDA approval in the same indications as reference denosumab (Prolia and Xgeva).

Giredestrant Becomes First Oral SERD to Show iDFS Benefit As Adjuvant Therapy in Early ER+, HER2-Negative Breast Cancer

November 18th 2025

The phase 3 lidERA trial shows improved iDFS with giredestrant vs standard therapy in early ER-positive, HER2-negative breast cancer.

Gedatolisib NDA for HR+ PIK3CA Wild-Type Advanced Breast Cancer Has Been Submitted to the FDA

November 18th 2025

Gedatolisib’s NDA filing to the FDA is supported by VIKTORIA-1 data showing marked PFS improvements in HR+/HER2– advanced breast cancer.

Advances in Breast Cancer ADCs and Endocrine Therapy Take Center Stage at CFS: With Benjamin P. Levy, MD; Kamel Abou Hussein, MD; and Victoria Rizk, MD

November 17th 2025

Benjamin P. Levy, MD leads a live CFS discussion with Kamel Abou Hussein, MD and Victoria Rizk, MD on the evolving therapeutic landscape in breast cancer.

Dr Saad on the Rationale for AI-Generated Synthetic Cohorts in Metastatic Breast Cancer Research

November 14th 2025

Eddy Saad, MD, discusses how AI-generated synthetic cohorts derived from real-world data may accelerate trial design and collaboration in metastatic breast cancer.